KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,862 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,862 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64. Following the transaction, the chief financial officer directly owned 18,150 shares in the company, valued at approximately $366,993. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Piekos also recently made the following trade(s):

• On Monday, February 23rd, Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19.

KalVista Pharmaceuticals Stock Up 1.9%

Shares of KalVista Pharmaceuticals stock opened at $20.87 on Tuesday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company’s fifty day simple moving average is $17.50 and its two-hundred day simple moving average is $15.23. The company has a market cap of $1.07 billion, a P/E ratio of -5.28 and a beta of -0.40. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $21.31.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its stake in shares of KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 818 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the last quarter. Rhumbline Advisers grew its stake in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after acquiring an additional 1,458 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of KalVista Pharmaceuticals by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after acquiring an additional 2,402 shares during the last quarter. Finally, Profund Advisors LLC grew its stake in shares of KalVista Pharmaceuticals by 25.9% in the third quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock worth $154,000 after acquiring an additional 2,593 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright lifted their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC lifted their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Stifel Nicolaus lifted their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Citizens Jmp lowered their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Several sell‑side firms have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), and recent filings show large institutional stakes being established or increased — a combination that supports upward momentum and a consensus target materially above the current price. MarketBeat coverage
• Neutral Sentiment: Company fundamentals and technicals offer context: market cap ≈ $1.07B, very strong liquidity (current and quick ratios ≈7.2) and the 50‑day / 200‑day moving averages ($17.50 / $15.23) sit below the current trade — supportive background but not an immediate catalyst for price moves.
• Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares at ~$20.22; CFO Brian Piekos and other insiders also sold smaller blocks). Filings say sales were to cover tax withholding on vested awards, but concentrated insider selling can still create short‑term downward pressure or investor concern. InsiderTrades alert

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.